AZD 6912
Alternative Names: AZD-6912Latest Information Update: 20 Jul 2024
At a glance
- Originator AstraZeneca
- Class Antirheumatics
- Mechanism of Action Complement factor B expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 12 Jun 2024 Updated pharmacodynamics data from a preclinical trial in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 15 Nov 2023 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in United Kingdom (SC) (NCT06115967)
- 03 Nov 2023 Preclinical trials in Rheumatoid arthritis in USA (SC)